Research Associate II, Translational In Vivo Pharmacology

OPPORTUNITY
Mammoth has an incredible opportunity for an innovative and motivated individual to join our expanding Gene Editing and Protein Discovery (GEPD) team as a Research Associate II. The incumbent's primary role will be to drive and execute the preclinical in vivo proof of concept and IND-enabling studies for Mammoth research programs.
KEY RESPONSIBILITIES

• Identify, design, establish, and execute preclinical in vivo studies to support and advance Mammoth research projects in, but not limited to, hematology, oncology, and therapeutic delivery and safety
• Establish and maintain IACUC protocols, amendments, and SOPs
• Perform data analysis, presentation of results to project teams, and technical report writing
• Maintain accurate, detailed, and timely documentation in electronic laboratory notebook
• Collaboration with project team members to coordinate research studies to meet project timelines

REQUIRED QUALIFICATIONS

• Small animal in vivo technical skills including various routes of administration, sample collection, and minor surgical procedures
• 4+ yeas of laboratory animal experience

PREFERRED QUALIFICATIONS

• Prior experience with humanized and transgenic mouse models
• Gene editing delivery with AAV and/or LNP
• Cell culture (human, mammalian, and tumor cells), flow cytometry, histology, and/or other molecular biology experience
• Be able to work as part of a team as well as independently with minimal to no supervision
• Strong communication skills
• Meticulous experimental record keeping
• Ability to work occasional off-hours, holidays, and weekends

BENEFITS

• Company-paid health/vision/dental benefits
• Unlimited vacation and generous sick time
• Company-sponsored meals and snacks
• Wellness, caregiver and ergonomics benefits
• 401(k) with company matching

Mammoth Biosciences is harnessing the diversity of life to power the next generation of CRISPR products. Through the discovery and engineering of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth aims to develop permanent genetic cures through best-in-class in vivo and ex vivo therapies and to democratize disease detection with on-demand diagnostics. Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in the San Francisco Bay Area, Mammoth Biosciences is co-founded by CRISPR pioneer and Nobel Laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Redmile Group, Foresite Capital, Senator Investment Group, Sixth Street, Decheng, Mayfield, NFX, and 8VC, along with leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.

TEAM
Our small-size proteins, such as Cas14 and CasPhi, are poised to transform disease treatment enabling novel editing approaches and delivery options that are difficult to achieve or not even possible with previously described CRISPR-Cas systems. Our teams are responsible for discovering and engineering novel CRISPR systems, establishing CRISPR-based diagnostics, and translating our unique CRISPR technology into therapeutic treatments with the ultimate goal of cures for indications with high medical need.

It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.

Mammoth Biosciences requires that all employees be vaccinated against Covid-19 as a condition of at-will employment, with exceptions for medical or religious reasons in compliance with local, state, and federal law.